XLIF
Device
NUVASIVE, INC.
Total Payments
$26.1M
Transactions
30,682
Doctors
3,351
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.0M | 2,018 | 552 |
| 2023 | $2.7M | 3,607 | 820 |
| 2022 | $3.9M | 4,037 | 811 |
| 2021 | $4.5M | 4,018 | 836 |
| 2020 | $3.8M | 2,589 | 607 |
| 2019 | $3.7M | 5,245 | 957 |
| 2018 | $3.5M | 4,687 | 907 |
| 2017 | $2.1M | 4,481 | 838 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14.4M | 1,732 | 55.0% |
| Royalty or License | $3.0M | 101 | 11.7% |
| Unspecified | $3.0M | 825 | 11.5% |
| Travel and Lodging | $2.6M | 11,049 | 10.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1.6M | 517 | 6.2% |
| Food and Beverage | $974,789 | 16,306 | 3.7% |
| Space rental or facility fees (teaching hospital only) | $371,639 | 55 | 1.4% |
| Grant | $28,870 | 2 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,775 | 4 | 0.1% |
| Education | $22,612 | 43 | 0.1% |
| Entertainment | $2,074 | 47 | 0.0% |
| Gift | $37.06 | 1 | 0.0% |
Payments by Type
General
$23.1M
29,857 transactions
Research
$3.0M
825 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | NuVasive, Inc. | $1.0M | 1 |
| NUVA.X1801: A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF?? Surgery | NuVasive, Inc. | $438,243 | 0 |
| A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | Globus Medical, Inc. | $293,417 | 0 |
| A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF Surgery | NuVasive, Inc. | $208,919 | 0 |
| NUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | Globus Medical, Inc. | $199,842 | 1 |
| A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF Surgery | Globus Medical, Inc. | $194,898 | 0 |
| A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | NuVasive, Inc. | $132,245 | 0 |
| NUVA.X1801 A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF?? Surgery | NuVasive, Inc. | $128,312 | 0 |
| NUVA.X1801 A Prospective Multicenter Study Evaluating the Effect of Implant Material andor Surface Structure on Progression of Fusion in XLIF Surgery | NuVasive, Inc. | $120,483 | 0 |
| NUVA.X1801: A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF?? Surgery | Globus Medical, Inc. | $62,031 | 0 |
| A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF Surgery (Enrolling by invitation) | Globus Medical, Inc. | $52,203 | 0 |
| NUVA.DEC08020: A prospective, multicenter study evaluating the safety and performance of the NuVasive?? XLIF Decade??? Plate System for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | NuVasive, Inc. | $35,813 | 0 |
| A Prospective, Multicenter Study Evaluating the Safety and Performance of the NuVasive XLIF Decade Plate System for the Treatment of Patients With Degenerative Conditions of the Thoracic and/or Lumbar Spine | NuVasive, Inc. | $19,350 | 0 |
| NUVA.X1901: An assessment of the safety and performance of the Modulus?? 3D-printed titanium interbody implant in patients undergoing eXtreme Lateral Interbody Fusion (XLIF??) | NuVasive, Inc. | $13,800 | 1 |
| NUVA.LIB1119 A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | NuVasive, Inc. | $10,950 | 0 |
| NUVA.ACP0721: A prospective, multicenter study evaluating the safety and performance of the NuVasive?? ACP System for the treatment of patients with pathologic conditions of the cervical spine | NuVasive, Inc. | $8,800 | 0 |
| NUVA.IGA1503 A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used | NuVasive, Inc. | $8,325 | 0 |
| An Assessment of the Safety and Performance of the Modulus 3D-printed Titanium Interbody Implant in Patients Undergoing eXtreme Lateral Interbody Fusion (XLIF) | Globus Medical, Inc. | $4,804 | 1 |
| NUVA.CIB0420: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the cervical spine | NuVasive, Inc. | $4,532 | 0 |
| An Assessment of the Safety and Performance of the Modulus 3D-printed Titanium Interbody Implant in Patients Undergoing eXtreme Lateral Interbody Fusion (XLIF) | NuVasive, Inc. | $4,040 | 0 |
Top Doctors Receiving Payments for XLIF — Page 133
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Neurological Surgery | Houston, TX | $13.09 | 1 |
| , MD | Neurological Surgery | Cleveland, OH | $12.97 | 1 |
| , MD | Neurological Surgery | Woodbury, NJ | $12.92 | 1 |
| Vivek Sharma | Orthopaedic Surgery | Uniontown, PA | $12.79 | 1 |
| , M.D | Orthopaedic Surgery | Grand Rapids, MI | $12.75 | 1 |
| , M.D, | Specialist | Birmingham, AL | $12.68 | 1 |
| , M.D | Specialist | Birmingham, AL | $12.68 | 1 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Bismarck, ND | $12.58 | 1 |
| , M.D | Orthopaedic Surgery | La Jolla, CA | $12.46 | 1 |
| , M.D | Neurological Surgery | Paoli, PA | $12.35 | 1 |
| , MD | Neurological Surgery | Boston, MA | $12.32 | 1 |
| , M.D | Neurological Surgery | Littleton, CO | $12.29 | 1 |
| , M.D | Orthopaedic Surgery | Oregon, OH | $12.23 | 1 |
| , D.P.M | Podiatrist | Culver City, CA | $12.21 | 1 |
| , M.D | Neurological Surgery | La Jolla, CA | $12.17 | 1 |
| , MD | Neurological Surgery | Salt Lake City, UT | $12.13 | 1 |
| , MD | Orthopaedic Surgery of the Spine | Chicago, IL | $12.11 | 1 |
| , PA-C, MPH, MSPAS | Physician Assistant | Santa Cruz, CA | $12.02 | 1 |
| , MD | Orthopaedic Surgery | Englewood, NJ | $12.00 | 1 |
| , MD, PHD | Orthopaedic Surgery of the Spine | Clearwater, FL | $12.00 | 1 |
| , M.D., PH.D | Neurological Surgery | San Francisco, CA | $12.00 | 1 |
| , M.D | Surgery | Rio Piedras, PR | $11.99 | 1 |
| , MD | Neurological Surgery | Grand Rapids, MI | $11.89 | 1 |
| , MD | Neurological Surgery | Miami Beach, FL | $11.76 | 1 |
| , M.D | Neurological Surgery | Toledo, OH | $11.69 | 1 |
Ad
Manufacturing Companies
- NuVasive, Inc. $22.0M
- NUVASIVE, INC. $2.1M
- Globus Medical, Inc. $2.0M
- Renovis Surgical Technologies, Inc. $1,350
Product Information
- Type Device
- Total Payments $26.1M
- Total Doctors 3,351
- Transactions 30,682
About XLIF
XLIF is a device associated with $26.1M in payments to 3,351 healthcare providers, recorded across 30,682 transactions in the CMS Open Payments database. The primary manufacturer is NUVASIVE, INC..
Payment data is available from 2017 to 2024. In 2024, $2.0M was paid across 2,018 transactions to 552 doctors.
The most common payment nature for XLIF is "Consulting Fee" ($14.4M, 55.0% of total).
XLIF is associated with 20 research studies, including "NUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine" ($1.0M).